Insmed (INSM) EBT Growth (1y) (2011 - 2026)

Insmed (INSM) EBT Growth (1y) (2011 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Growth (1y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 8.48%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 0.60%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 88.57%
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 213.87%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 76.48%
7 Royalty Pharma 33.72 Bn 35.84 Bn - -12.04%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 530.43%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 96.45%
10 Roivant Sciences 26.16 Bn 26.85 Bn 1.16 Mn -

Historic Data

Download Data
DateValue
Jun 30, 2026 96.45%
Mar 31, 2026 36.60%
Dec 31, 2025 -39.55%
Sep 30, 2025 -67.97%
Jun 30, 2025 -6.90%
Mar 31, 2025 -63.37%
Dec 31, 2024 -26.60%
Sep 30, 2024 -38.59%
Jun 30, 2024 -22.72%
Mar 31, 2024 1.74%
Dec 31, 2023 -15.67%
Sep 30, 2023 -21.12%
Jun 30, 2023 -156.75%
Mar 31, 2023 -69.02%
Dec 31, 2022 -41.57%
Sep 30, 2022 -13.43%
Jun 30, 2022 18.47%
Mar 31, 2022 -3.10%
Dec 31, 2021 -11.25%
Sep 30, 2021 -82.02%